On Nov. 1, 2025, roughly three years and a month after Bernice’s death, the class complaint was settled and PHSA, BCTS and ...

Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline ...

With smart DMPK strategies, cross-domain collaboration, and strong CDMO support, companies are pushing past the challenges of ...

Zurich (Switzerland), January 7, 2026 - GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to ...

Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical ...

(MENAFN- EIN Presswire) EINPresswire/ -- "The Primary Biliary Cholangitis market is dominated by a mix of global leading pharmaceutical companies and emerging biotechnology innovators. Companies are ...

—A recent study found that overall pathological changes of antibody-negative primary biliary cholangitis (PBC) were slightly milder than those of antibody-positive PBC, suggesting these 2 types of PBC ...

Hear from Anna who is living with a rare liver disease called primary biliary cholangitis (PBC) and inspiring others to speak up and advocate for their health. Anna has been compensated by Ipsen for ...

Primary biliary cholangitis is a chronic autoimmune liver disease. In recent years, gut microbiota dysbiosis has emerged as a key research focus in PBC. This review summarizes how gut microbiota ...

Gilead Sciences, Inc. today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi ® for people living with primary biliary cholangitis. These findings were presented at ...